[10-Q] Sleep Number Corporation Quarterly Earnings Report

Rhea-AI Filing Summary

Sleep Number (SNBR) Q2 2025 10-Q highlights: Net sales fell 20% YoY to $327.9 million as retail comparable sales declined 19% and store count dropped to 630. Six-month sales decreased 18% to $721.2 million. Gross margin held at 59.1%, benefiting from 140 bp of product-cost savings offset by unfavorable mix and higher warranty/return costs.

Operating loss was $0.1 million (vs. $6.1 million profit LY) after $8.3 million of restructuring charges. Net loss widened to $25.0 million ($1.09 per diluted share); YTD loss is $33.7 million. Adjusted EBITDA slipped to $23.6 million from $28.3 million.

Cost-reduction program has generated $42.2 million cumulative charges and projects another ~$8 million in 2H 2025. Operating expenses were $42 million lower YoY, driven by 32% cut in media spend and lower incentive comp.

Balance sheet & liquidity: Cash was just $1.3 million; free cash flow burned $6.9 million YTD. Revolver borrowings rose to $563.9 million (7.9% weighted-avg rate), pushing leverage to 4.6×—just below the amended 4.75× covenant. The March 2025 credit amendment introduced a minimum $40 million liquidity covenant and step-down leverage/coverage targets through 2026; company remains compliant with $102 million revolver availability.

Outlook risks: sustained demand weakness in a multi-year mattress downturn, elevated interest costs, valuation allowance adding $14 million tax expense, further restructuring outlays, and pending California class-action litigation. Management is prioritizing margin initiatives, cash generation, and reduced capex ($8 million YTD) while evaluating impact of the newly enacted OBBBA tax law.

Positive

• Gross margin stable at 59.1% despite 20% revenue drop, reflecting successful product cost reductions and pricing discipline.
• Operating expenses down $42 million YoY through media cuts and headcount actions, signalling management focus on cost control.
• Covenant compliance maintained after March 2025 amendment; leverage 4.6× below 4.75× limit and liquidity availability of $102 million.
• Adjusted EBITDA positive at $23.6 million for the quarter, providing some cash generation capability.

Negative

• Net sales declined 20% QoQ YoY, continuing multi-year demand weakness and lowering scale efficiency.
• Net loss widened to $25 million; YTD loss $33.7 million indicates worsening profitability.
• High leverage with $563.9 million debt and just $1.3 million cash; interest expense consumes 3.6% of sales.
• Free cash flow negative $6.9 million YTD; limited liquidity headroom under new $40 million covenant.
• Additional restructuring costs (~$8 million) and class-action litigation pose further earnings and cash risks.
• Valuation allowance of $14 million increased tax expense, reducing future tax asset utility.

Insights

Equity Research Analyst

TL;DR: Revenue plunge offsets margin gains; leverage tight but covenants met—overall negative for equity holders.

The 20% sales contraction underscores continued bedding recession and reduced store footprint. Stable 59.1% GM shows value-engineering traction, yet cannot offset volume loss. Operating cash flow of just $1 million and $564 million debt leave little room for error; liquidity covenant at $40 million is uncomfortably close with only $102 million availability and $1 million cash. Adjusted EBITDA coverage (1.9× interest) barely clears amended thresholds. Planned restructuring savings help but add ~$8 million charges ahead. The $14 million valuation allowance raises effective tax drag, signalling limited near-term tax benefits. Unless demand recovers, equity value is pressured by leverage and covenant risk.

Credit Risk Specialist

TL;DR: Covenant amendment provides headroom, but high rate debt and cash burn keep credit profile fragile.

Revolver utilisation at 84% with 7.9% cost elevates interest burden ($46.6 million TTM). Amendment lifts max leverage to 4.75× this quarter and installs $40 million liquidity floor. Current 4.6× leverage and $102 million unused commitments offer modest buffer; any further EBITDA erosion could trigger defaults. Positive factors: consistent gross margins, $436 million lease-adjusted payments well laddered, and ability to reduce capex. Upcoming OBBBA may improve cash taxes via bonus depreciation, but impact not yet quantified. Overall, debt outlook is cautious but not immediately distressed—creditors should monitor Q3 EBITDA trajectory and progress on restructuring savings.

000082718701/032025Q2FALSEP5YP3Yxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:puresnbr:segment00008271872024-12-292025-06-2800008271872025-06-2800008271872024-12-2800008271872025-03-302025-06-2800008271872024-03-312024-06-2900008271872023-12-312024-06-290000827187us-gaap:CommonStockMember2024-12-280000827187us-gaap:AdditionalPaidInCapitalMember2024-12-280000827187us-gaap:RetainedEarningsMember2024-12-280000827187us-gaap:RetainedEarningsMember2024-12-292025-03-2900008271872024-12-292025-03-290000827187us-gaap:CommonStockMember2024-12-292025-03-290000827187us-gaap:AdditionalPaidInCapitalMember2024-12-292025-03-290000827187us-gaap:CommonStockMember2025-03-290000827187us-gaap:AdditionalPaidInCapitalMember2025-03-290000827187us-gaap:RetainedEarningsMember2025-03-2900008271872025-03-290000827187us-gaap:RetainedEarningsMember2025-03-302025-06-280000827187us-gaap:CommonStockMember2025-03-302025-06-280000827187us-gaap:AdditionalPaidInCapitalMember2025-03-302025-06-280000827187us-gaap:CommonStockMember2025-06-280000827187us-gaap:AdditionalPaidInCapitalMember2025-06-280000827187us-gaap:RetainedEarningsMember2025-06-280000827187us-gaap:CommonStockMember2023-12-300000827187us-gaap:AdditionalPaidInCapitalMember2023-12-300000827187us-gaap:RetainedEarningsMember2023-12-3000008271872023-12-300000827187us-gaap:RetainedEarningsMember2023-12-312024-03-3000008271872023-12-312024-03-300000827187us-gaap:CommonStockMember2023-12-312024-03-300000827187us-gaap:AdditionalPaidInCapitalMember2023-12-312024-03-300000827187us-gaap:CommonStockMember2024-03-300000827187us-gaap:AdditionalPaidInCapitalMember2024-03-300000827187us-gaap:RetainedEarningsMember2024-03-3000008271872024-03-300000827187us-gaap:RetainedEarningsMember2024-03-312024-06-290000827187us-gaap:CommonStockMember2024-03-312024-06-290000827187us-gaap:AdditionalPaidInCapitalMember2024-03-312024-06-290000827187us-gaap:CommonStockMember2024-06-290000827187us-gaap:AdditionalPaidInCapitalMember2024-06-290000827187us-gaap:RetainedEarningsMember2024-06-2900008271872024-06-290000827187us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-12-280000827187us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-06-280000827187us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-12-280000827187us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-06-280000827187us-gaap:TradeNamesMember2025-06-280000827187us-gaap:TradeNamesMember2024-12-280000827187us-gaap:PatentsMember2025-06-280000827187us-gaap:PatentsMember2024-12-280000827187us-gaap:PatentsMember2024-03-312024-06-290000827187us-gaap:PatentsMember2025-03-302025-06-280000827187us-gaap:PatentsMember2023-12-312024-06-290000827187us-gaap:PatentsMember2024-12-292025-06-280000827187us-gaap:LineOfCreditMember2025-06-280000827187us-gaap:LineOfCreditMember2025-03-030000827187us-gaap:LineOfCreditMembersnbr:DebtCovenantPeriodOneMember2025-03-030000827187us-gaap:LineOfCreditMembersnbr:DebtCovenantPeriodTwoMember2025-03-030000827187us-gaap:LineOfCreditMembersnbr:DebtCovenantPeriodThreeMember2025-03-030000827187us-gaap:LineOfCreditMembersnbr:DebtCovenantPeriodFourMember2025-03-030000827187us-gaap:LineOfCreditMember2025-03-032025-03-030000827187us-gaap:SubsequentEventMember2025-06-290000827187srt:MinimumMembersnbr:RetailStoreLeasesMember2025-06-280000827187srt:MaximumMembersnbr:RetailStoreLeasesMember2025-06-280000827187srt:MaximumMembersnbr:OfficeAndManufacturingLeasesMember2025-06-280000827187srt:MinimumMembersnbr:LeaseVehiclesAndCertainEquipmentUnderOperatingLeasesMember2025-06-280000827187srt:MaximumMembersnbr:LeaseVehiclesAndCertainEquipmentUnderOperatingLeasesMember2025-06-280000827187us-gaap:OtherCurrentAssetsMember2025-06-280000827187us-gaap:OtherCurrentAssetsMember2024-12-280000827187us-gaap:OtherNoncurrentAssetsMember2025-06-280000827187us-gaap:OtherNoncurrentAssetsMember2024-12-280000827187us-gaap:OtherCurrentLiabilitiesMember2025-06-280000827187us-gaap:OtherCurrentLiabilitiesMember2024-12-280000827187us-gaap:OtherNoncurrentLiabilitiesMember2025-06-280000827187us-gaap:OtherNoncurrentLiabilitiesMember2024-12-280000827187snbr:SleepIQTechnologyMembersrt:MinimumMember2024-12-292025-06-280000827187snbr:SleepIQTechnologyMembersrt:MaximumMember2024-12-292025-06-280000827187snbr:TimingOfTransferOfGoodsOrServicesConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:TransferredAtPointInTimeMember2024-12-292025-06-280000827187snbr:TimingOfTransferOfGoodsOrServicesConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:TransferredAtPointInTimeMember2023-12-312024-06-290000827187snbr:TimingOfTransferOfGoodsOrServicesConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:TransferredAtPointInTimeMember2024-03-312024-06-290000827187snbr:TimingOfTransferOfGoodsOrServicesConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:TransferredAtPointInTimeMember2025-03-302025-06-280000827187snbr:RetailChannelMember2025-03-302025-06-280000827187snbr:RetailChannelMember2024-03-312024-06-290000827187snbr:RetailChannelMember2024-12-292025-06-280000827187snbr:RetailChannelMember2023-12-312024-06-290000827187snbr:OnlinePhoneChatAndOtherMember2025-03-302025-06-280000827187snbr:OnlinePhoneChatAndOtherMember2024-03-312024-06-290000827187snbr:OnlinePhoneChatAndOtherMember2024-12-292025-06-280000827187snbr:OnlinePhoneChatAndOtherMember2023-12-312024-06-290000827187snbr:TimeBasedPerformanceBasedAndMarketBasedStockAwardsMember2025-03-302025-06-280000827187snbr:TimeBasedPerformanceBasedAndMarketBasedStockAwardsMember2024-03-312024-06-290000827187snbr:TimeBasedPerformanceBasedAndMarketBasedStockAwardsMember2024-12-292025-06-280000827187snbr:TimeBasedPerformanceBasedAndMarketBasedStockAwardsMember2023-12-312024-06-290000827187us-gaap:EmployeeStockOptionMember2025-03-302025-06-280000827187us-gaap:EmployeeStockOptionMember2024-03-312024-06-290000827187us-gaap:EmployeeStockOptionMember2024-12-292025-06-280000827187us-gaap:EmployeeStockOptionMember2023-12-312024-06-2900008271872023-10-012024-12-280000827187srt:MinimumMember2025-06-280000827187us-gaap:ContractTerminationMember2025-03-302025-06-280000827187us-gaap:ContractTerminationMember2024-03-312024-06-290000827187us-gaap:ContractTerminationMember2024-12-292025-06-280000827187us-gaap:ContractTerminationMember2023-12-312024-06-290000827187us-gaap:EmployeeSeveranceMember2025-03-302025-06-280000827187us-gaap:EmployeeSeveranceMember2024-03-312024-06-290000827187us-gaap:EmployeeSeveranceMember2024-12-292025-06-280000827187us-gaap:EmployeeSeveranceMember2023-12-312024-06-290000827187snbr:ProfessionalFeesMember2025-03-302025-06-280000827187snbr:ProfessionalFeesMember2024-03-312024-06-290000827187snbr:ProfessionalFeesMember2024-12-292025-06-280000827187snbr:ProfessionalFeesMember2023-12-312024-06-2900008271872023-12-312024-12-2800008271872023-10-012025-06-280000827187us-gaap:ContractTerminationMember2023-10-012025-06-280000827187us-gaap:EmployeeSeveranceMember2023-10-012025-06-280000827187snbr:ProfessionalFeesMember2023-10-012025-06-280000827187snbr:ReportableSegmentMember2025-03-302025-06-280000827187snbr:ReportableSegmentMember2024-03-312024-06-290000827187snbr:ReportableSegmentMember2024-12-292025-06-280000827187snbr:ReportableSegmentMember2023-12-312024-06-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 28, 2025

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 000-25121

_______________________________________________________________________

SLEEP NUMBER CORPORATION

(Exact name of registrant as specified in its charter)

Minnesota		41-1597886
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

1001 Third Avenue South
Minneapolis,		Minnesota		55404
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: (763) 551-7000

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01 per share		SNBR		Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities

Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),

and (2) has been subject to such filing requirements for the past 90 days. Yes  ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted

pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the

registrant was required to submit such files). Yes  ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller

reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller

reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐		Accelerated filer	☒
Non-accelerated filer	☐		Smaller reporting company	☐
			Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for

complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  ☐ No ☒

As of June 28, 2025, 22,771,000 shares of the registrant’s Common Stock were outstanding.

i | 2Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION

Table of contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

INDEX

		Page
PART I: FINANCIAL INFORMATION		1
Item 1.	Financial Statements (unaudited)	1
	Condensed Consolidated Balance Sheets	1
	Condensed Consolidated Statements of Operations	2
	Condensed Consolidated Statements of Shareholders' Deficit	3
	Condensed Consolidated Statements of Cash Flows	4
	Notes to Condensed Consolidated Financial Statements	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	27
Item 4.	Controls and Procedures	27
PART II: OTHER INFORMATION		28
Item 1.	Legal Proceedings	28
Item 1A.	Risk Factors	28
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	28
Item 3.	Defaults Upon Senior Securities	28
Item 4.	Mine Safety Disclosures	28
Item 5.	Other Information	28
Item 6.	Exhibits	29
SIGNATURES		31

1 | 2Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION

Table of contents

PART I: FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(unaudited - in thousands, except per share amounts)

	June 28, 2025		December 28, 2024
Assets
Current assets:
Cash and cash equivalents	$1,349		$1,950
Accounts receivable, net of allowances of $1,127 and $1,113, respectively	16,017		17,516
Inventories	99,450		103,152
Prepaid expenses	20,824		14,568
Other current assets	37,885		44,098
Total current assets	175,525		181,284
Non-current assets:
Property and equipment, net	109,105		129,574
Operating lease right-of-use assets	339,149		356,641
Goodwill and intangible assets, net	66,301		66,412
Deferred income taxes	31,803		33,575
Other non-current assets	82,629		93,324
Total assets	$804,512		$860,810
Liabilities and Shareholders’ Deficit
Current liabilities:
Borrowings under revolving credit facility	$563,900		$546,600
Accounts payable	111,212		107,619
Customer prepayments	41,141		46,933
Accrued sales returns	15,650		19,092
Compensation and benefits	20,929		31,038
Taxes and withholding	17,854		18,619
Operating lease liabilities	82,209		82,307
Other current liabilities	50,326		55,804
Total current liabilities	903,221		908,012
Non-current liabilities:
Operating lease liabilities	287,585		307,201
Other non-current liabilities	94,394		97,183
Total liabilities	1,285,200		1,312,396
Shareholders’ deficit:
Undesignated preferred stock; 5,000 shares authorized, no shares issued and outstanding	—		—
Common stock, $0.01 par value; 142,500 shares authorized, 22,771 and 22,388 shares issued and outstanding, respectively	228		224
Additional paid-in capital	31,942		27,390
Accumulated deficit	(512,858)		(479,200)
Total shareholders’ deficit	(480,688)		(451,586)
Total liabilities and shareholders’ deficit	$804,512		$860,810

See accompanying notes to condensed consolidated financial statements.

2 | 2Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION

Table of contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(unaudited - in thousands, except per share amounts)

	Three Months Ended				Six Months Ended
	June 28, 2025		June 29, 2024		June 28, 2025		June 29, 2024
Net sales	$327,925		$408,413		$721,186		$878,862
Cost of sales	134,180		166,923		286,906		361,198
Gross profit	193,745		241,490		434,280		517,664
Operating expenses:
Sales and marketing	146,464		182,400		335,567		390,912
General and administrative	29,604		39,573		68,223		78,652
Research and development	9,420		11,578		20,323		24,019
Restructuring costs	8,332		1,819		8,392		12,419
Total operating expenses	193,820		235,370		432,505		506,002
Operating (loss) income	(75)		6,120		1,775		11,662
Interest expense, net	11,734		12,270		22,815		24,569
Loss before income taxes	(11,809)		(6,150)		(21,040)		(12,907)
Income tax expense (benefit)	13,203		(1,099)		12,618		(374)
Net loss	$(25,012)		$(5,051)		$(33,658)		$(12,533)
Basic net loss per share:
Net loss per share – basic	$(1.09)		$(0.22)		$(1.48)		$(0.56)
Weighted-average shares – basic	22,903		22,614		22,804		22,560
Diluted net loss per share:
Net loss per share – diluted	$(1.09)		$(0.22)		$(1.48)		$(0.56)
Weighted-average shares – diluted	22,903		22,614		22,804		22,560

See accompanying notes to condensed consolidated financial statements.

3 | 2Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION

Table of contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Condensed Consolidated Statements of Shareholders’ Deficit

(unaudited - in thousands)

	Common Stock				Additional Paid-in Capital		Accumulated Deficit		Total
	Shares		Amount
Balance at December 28, 2024	22,388		$224		$27,390		$(479,200)		$(451,586)
Net loss	—		—		—		(8,646)		(8,646)
Stock-based compensation	346		3		3,948		—		3,951
Repurchases of common stock	(74)		—		(563)		—		(563)
Balance at March 29, 2025	22,660		$227		$30,775		$(487,846)		$(456,844)
Net loss	—		—		—		(25,012)		(25,012)
Stock-based compensation	149		1		1,548		—		1,549
Repurchases of common stock	(38)		—		(381)		—		(381)
Balance at June 28, 2025	22,771		$228		$31,942		$(512,858)		$(480,688)

	Common Stock				Additional Paid-in Capital		Accumulated Deficit		Total
	Shares		Amount
Balance at December 30, 2023	22,235		$222		$16,716		$(458,866)		$(441,928)
Net loss	—		—		—		(7,482)		(7,482)
Stock-based compensation	134		1		4,116		—		4,117
Repurchases of common stock	(43)		—		(570)		—		(570)
Balance at March 30, 2024	22,326		$223		$20,262		$(466,348)		$(445,863)
Net loss	—		—		—		(5,051)		(5,051)
Stock-based compensation	32		1		3,991		—		3,992
Repurchases of common stock	(3)		—		(42)		—		(42)
Balance at June 29, 2024	22,355		$224		$24,211		$(471,399)		$(446,964)

See accompanying notes to condensed consolidated financial statements.

4 | 2Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION

Table of contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(unaudited - in thousands)

	Six Months Ended
	June 28, 2025		June 29, 2024
Cash flows from operating activities:
Net loss	$(33,658)		$(12,533)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	29,096		34,177
Stock-based compensation	5,500		8,109
Net loss on disposals and impairments of assets	775		2,500
Deferred income taxes	1,772		(5,144)
Changes in operating assets and liabilities:
Accounts receivable	1,499		6,587
Inventories	3,702		19,588
Income taxes	2,470		774
Prepaid expenses and other assets	10,381		(1,483)
Accounts payable	8,354		(18,464)
Customer prepayments	(5,792)		(4,625)
Accrued compensation and benefits	(10,086)		7,153
Other taxes and withholding	(3,235)		(1,345)
Other accruals and liabilities	(9,582)		(11,776)
Net cash provided by operating activities	1,196		23,518
Cash flows from investing activities:
Purchases of property and equipment	(8,052)		(14,075)
Payment to secure contractual rights	(3,280)		—
Issuance of note receivable	—		(2,942)
Net cash used in investing activities	(11,332)		(17,017)
Cash flows from financing activities:
Net increase (decrease) in short-term borrowings	12,356		(6,408)
Repurchases of common stock	(944)		(612)
Debt issuance costs	(1,877)		—
Net cash provided by (used in) financing activities	9,535		(7,020)
Net decrease in cash and cash equivalents	(601)		(519)
Cash and cash equivalents, at beginning of period	1,950		2,539
Cash and cash equivalents, at end of period	$1,349		$2,020

See accompanying notes to condensed consolidated financial statements.

5 | 2Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

 1. Business and Summary of Significant Accounting Policies

Business & Basis of Presentation

The Company prepared the condensed consolidated financial statements as of and for the three and six months ended

June 28, 2025 of Sleep Number Corporation and its 100%-owned subsidiaries (Sleep Number or the Company), without

audit, pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) and they reflect, in the

opinion of management, all normal recurring adjustments, including the elimination of all significant intra-entity balances

and transactions, necessary to present fairly its financial position as of June 28, 2025 and December 28, 2024, and the

consolidated results of operations and cash flows for the periods presented. The historical and quarterly consolidated

results of operations may not be indicative of the results that may be achieved for the full year or any future period.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S.

Generally Accepted Accounting Principles (GAAP) have been condensed or omitted pursuant to such rules and

regulations. These condensed consolidated financial statements should be read in conjunction with the most recent

audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for

the fiscal year ended December 28, 2024 and other recent filings with the SEC.

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the Company to

make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities,

disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the

reported amounts of sales, expenses and income taxes during the reporting period. Predicting future events is inherently

an imprecise activity and, as such, requires the use of judgment. As future events and their effects cannot be determined

with precision, actual results could differ significantly from these estimates. Changes in these estimates will be reflected

in the consolidated financial statements in future periods and could be material.

The Company’s critical accounting policies consist of stock-based compensation, warranty liabilities and revenue

recognition.

Accounting Pronouncements Issued But Not Yet Effective

In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements in Income Tax Disclosures"

to enhance the transparency and decision usefulness of income tax disclosures. This amendment requires public

companies to disclose specific categories in the rate reconciliation and provide additional information for reconciling

items that meet a quantitative threshold. Additionally, under the amendment, entities are required to disclose the

amount of income taxes paid disaggregated by federal, state and foreign taxes, as well as disaggregated by material

individual jurisdictions. Finally, the amendment requires entities to disclose income from continuing operations before

income tax expense disaggregated between domestic and foreign and income tax expense from continuing operations

disaggregated by federal, state and foreign. The new rules are effective for annual periods beginning after December

15, 2024. The adoption of this standard is not expected to have a material impact on the Company’s consolidated

financial statements and related disclosures.

In November 2024, the FASB issued ASU 2024-03, "Income Statement - Reporting Comprehensive Income - Expense

Disaggregation Disclosures (Subtopic 220-40)", which requires public business entities to disclose in the notes to the

financial statements more detailed information about the types of expenses included in certain expense captions in the

consolidated financial statements, including purchases of inventory, employee compensation, and depreciation and

amortization. The amendments are effective for the Company beginning with the 2027 annual period and in interim

periods beginning in 2028. Early adoption is permitted. The ASU may be adopted prospectively or retrospectively. The

Company is currently evaluating the impact of ASU 2024-03 on its consolidated financial statements and related

disclosures.

Currently, management does not believe that any other recently issued, but not yet effective accounting

pronouncements, if adopted in their current form, would have a material impact on the Company’s consolidated financial

statements.

6 | 2Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

Other Investments

The Company made a payment of $3.3 million during the three months ended June 28, 2025 to secure contractual rights

from a strategic product-development partner. This payment is included in prepaid expenses in the Company’s

condensed consolidated balance sheet and as an investing activity in the Company’s condensed consolidated statement

of cash flows.

 2. Fair Value Measurements

At both June 28, 2025 and December 28, 2024, the Company had $19 million of debt and equity securities that fund the

deferred compensation plan and are classified in other non-current assets. The Company also had corresponding

deferred compensation plan liabilities of $19 million at both June 28, 2025 and December 28, 2024 which are included

in other non-current liabilities. The majority of the debt and equity securities are Level 1 as they trade with sufficient

frequency and volume to enable the Company to obtain pricing information on an ongoing basis. Unrealized gains/

(losses) on the debt and equity securities offset those associated with the corresponding deferred compensation plan

liabilities.

 3. Inventories

Inventories consisted of the following (in thousands):

	June 28, 2025		December 28, 2024
Raw materials	$6,415		$11,434
Work in progress	168		130
Finished goods	92,867		91,588
	$99,450		$103,152

 4. Goodwill and Intangible Assets, Net

Goodwill and Indefinite-lived Intangible Assets

Goodwill was $64.0 million at June 28, 2025 and December 28, 2024. Indefinite-lived trade name/trademarks totaled

$1.4 million at both June 28, 2025 and December 28, 2024.

Definite-lived Intangible Assets

Patents were $2.0 million at both June 28, 2025 and December 28, 2024. Accumulated amortization was $1.1 million at

June 28, 2025 and $1.0 million at December 28, 2024. Amortization expense was $55 thousand for both the three

months ended June 28, 2025 and June 29, 2024, and $0.1 million for both the six months ended June 28, 2025 and

June 29, 2024.

Annual amortization for patents for subsequent years is as follows (in thousands):

2025 (excluding the six months ended June 28, 2025 )		$117
2026		222
2027		222
2028		155
2029		99
2030		45
Total future amortization for definite-lived intangible assets		$860

7 | 2Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

 5. Credit Agreement

As of June 28, 2025, the Company’s credit facility had a total commitment amount of $673 million. The credit facility, as

amended, is for general corporate purposes and to meet seasonal working capital requirements. The Amended and

Restated Credit and Security Agreement, dated February 14, 2018, among the Company, U.S. Bank National Association

and the several banks and other financial institutions from time to time party thereto (as amended, the Credit

Agreement), includes an accordion feature which allows the Company to increase the amount of the credit facility from

$673 million to $1.0 billion, subject to lenders’ approval. The Credit Agreement provides the lenders with a collateral

security interest in substantially all of the Company’s assets and those of its subsidiaries and requires the Company to

comply with, among other things, a maximum net leverage ratio and a minimum interest coverage ratio.

The Company amended the Credit Agreement on March 3, 2025. The amendment, among other things: (a) adds a

definition for "Liquidity" which means, on any date of determination, the sum of (x) Borrower's and its Subsidiaries'

unrestricted cash that is free and clear of Liens (other than those in favor of the Administrative Agent) plus (y) the

aggregate amount of unused Revolving Credit Commitments available for Credit Events on such date (including the

Borrower's ability to satisfy the requirements of Section 4.1 on such date) (as each is defined in the Credit Agreement);

(b) adds a Liquidity financial covenant wherein the Borrower shall cause the Liquidity to be equal or exceed $40 million

as of the last day of each fiscal month; (c) deems our Net Leverage Ratio as greater than or equal to 4.50 to 1.00 as of

the effective date to set pricing for the Applicable Commitment Fee Rate and Applicable Margin until receipt of the

compliance certificate for the quarterly reporting period ending September 27, 2025, (d) adjusts the permissible

maximum Net Leverage Ratio (as defined in the Credit Agreement) to (I) 4.75 to 1.00 for the quarterly reporting period

ending June 28, 2025, (II) 4.50 to 1.00 for the quarterly reporting period ending September 27, 2025, (III) 4.35 to 1.00 for

the quarterly reporting period ending January 3, 2026, and (IV) 4.00 to 1.00 for each quarterly reporting period occurring

thereafter, and (e) adjusts the permissible minimum Interest Coverage Ratio (as defined in the Credit Agreement) to (I)

1.90 to 1.00 for the quarterly reporting periods ending June 28, 2025 and September 27, 2025, (II) 2.10 to 1.00 for the

quarterly reporting period ending January 3, 2026, and (III) 3.00 to 1.00 for each quarterly reporting period occurring

thereafter. A fee for the amendment was paid to the approving lenders in an amount equal to 20 basis points multiplied

by the sum of such lender's Revolving Credit Commitment and outstanding Term Loans (as each is defined in the Credit

Agreement).

The carrying amount of the outstanding borrowings under the Credit Agreement approximates fair value because

interest rates approximate the current rates available to the Company. Under the terms of the Credit Agreement, the

Company pays a variable rate of interest and a commitment fee based on its leverage ratio. The Credit Agreement

matures in December 2026. The Company was in compliance with all financial covenants as of June 28, 2025.

The following table summarizes the Company’s borrowings under the credit facility ($ in thousands):

	June 28, 2025		December 28, 2024
Outstanding borrowings	$563,900		$546,600
Outstanding letters of credit	$6,847		$7,147
Additional borrowing capacity	$101,753		$123,753
Weighted-average interest rate	7.9%		7.6%

Subsequent to June 28, 2025, the Company’s outstanding letters of credit increased to $9 million.

 6. Leases

The Company leases its retail, office and manufacturing space under operating leases which, in addition to the minimum

lease payments, may require payment of a proportionate share of the real estate taxes and certain building operating

expenses. While the Company’s local market development approach generally results in long-term participation in given

markets, the retail store leases generally provide for an initial lease term of five to ten years. The Company’s office and

manufacturing leases provide for an initial lease term of up to fifteen years. In addition, the Company’s mall-based retail

store leases may require payment of variable rent based on net sales in excess of certain thresholds. Certain leases may

8 | 2Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

contain options to extend the term of the original lease. The exercise of lease renewal options is at the Company’s sole

discretion. Lease options are included in the lease term only if exercise is reasonably certain at lease commencement.

The Company’s lease agreements do not contain any material residual value guarantees. The Company also leases

vehicles and certain equipment under operating leases with an initial lease term of three to six years.

The Company’s operating lease costs include facility, vehicle and equipment lease costs, but exclude variable lease

costs. Operating lease costs are recognized on a straight-line basis over the lease term, after consideration of rent

escalations and rent holidays. The lease term for purposes of the calculation begins on the earlier of the lease

commencement date or the date the Company takes possession of the property. During lease renewal negotiations that

extend beyond the original lease term, the Company estimates straight-line rent expense based on current market

conditions. Variable lease costs are recorded when it is probable the cost has been incurred and the amount can be

reasonably estimated. Future payments for real estate taxes and certain building operating expenses for which the

Company is obligated are not included in operating lease costs.

At June 28, 2025, the Company’s finance right-of-use assets and lease liabilities were not significant.

Lease costs were as follows (in thousands):

	Three Months Ended				Six Months Ended
	June 28, 2025		June 29, 2024		June 28, 2025		June 29, 2024
Operating lease costs(1)	$26,649		$26,909		$53,186		$53,735
Variable lease costs(2)	$37		$8		$140		$(41)

___________________________

(1)Includes short-term lease costs which are not significant.

(2)Variable lease costs include adjustments to percentage rent.

The maturities of operating lease liabilities for subsequent years are as follows(1) (in thousands):

2025 (excluding the six months ended June 28, 2025)	$52,797
2026	99,002
2027	82,575
2028	69,001
2029	48,062
2030	34,064
Thereafter	51,219
Total operating lease payments(2)	436,720
Less: Interest	66,926
Present value of operating lease liabilities	$369,794

___________________________

(1)Total operating lease payments exclude $8 million of legally binding minimum lease payments for leases signed but not yet commenced.

(2)Includes the current portion of $82 million for operating lease liabilities.

Other information related to operating leases was as follows:

		June 28, 2025		December 28, 2024
Weighted-average remaining lease term (in years)		5.2		5.4
Weighted-average discount rate		6.7%		6.6%

9 | 2Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

		Six Months Ended
(in thousands)		June 28, 2025		June 29, 2024
Cash paid for amounts included in present value of operating lease liabilities		$53,092		$54,300
Right-of-use assets obtained in exchange for operating lease liabilities		$12,752		$16,313

 7. Repurchases of Common Stock

For the three months ended June 28, 2025 and June 29, 2024, we repurchased $0.4 million and $42 thousand,

respectively, of common stock in connection with the vesting of restricted stock grants. For the six months ended

June 28, 2025 and June 29, 2024, we repurchased $0.9 million and $0.6 million, respectively, of common stock in

connection with the vesting of restricted stock grants. We made no purchases under the Board-approved stock purchase

plan in either period. As of June 28, 2025, the remaining authorization under the Board-approved $600 million share

repurchase program was $348 million.

 8. Revenue Recognition

Deferred contract assets and deferred contract liabilities are included in the condensed consolidated balance sheets as

follows (in thousands):

	June 28, 2025		December 28, 2024
Deferred contract assets included in:
Other current assets	$28,793		$30,154
Other non-current assets	45,996		48,988
	$74,789		$79,142

	June 28, 2025		December 28, 2024
Deferred contract liabilities included in:
Other current liabilities	$37,008		$38,129
Other non-current liabilities	58,362		60,988
	$95,370		$99,117

Deferred revenue and costs related to SleepIQ® technology are currently recognized on a straight-line basis over the

product's estimated life of 4.5 to 5.0 years because the Company’s inputs are generally expended evenly throughout the

performance period. During the three months ended June 28, 2025 and June 29, 2024, the Company recognized

revenue of $7 million and $10 million, respectively, that was included in the deferred contract liability balances at the

beginning of the respective periods. During the six months ended June 28, 2025 and June 29, 2024, the Company

recognized revenue of $17 million and $19 million, respectively, that was included in the deferred contract liability

balances at the beginning of the respective periods.

Revenue from goods and services transferred to customers at a point in time accounted for approximately 98% of

revenues for both the three and six months ended June 28, 2025 and June 29, 2024.

10 | 2Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

Net sales were as follows (in thousands):

	Three Months Ended				Six Months Ended
	June 28, 2025		June 29, 2024		June 28, 2025		June 29, 2024
Retail stores	$287,974		$358,584		$632,415		$773,339
Online, phone, chat and other	39,951		49,829		88,771		105,523
Total Company	$327,925		$408,413		$721,186		$878,862

Obligation for Sales Returns

The activity in the sales returns liability account was as follows (in thousands):

	Six Months Ended
	June 28, 2025		June 29, 2024
Balance at beginning of year	$19,092		$22,402
Additions that reduce net sales	36,098		46,664
Deductions from reserves	(39,540)		(48,535)
Balance at end of period	$15,650		$20,531

 9. Stock-Based Compensation Expense

Total stock-based compensation expense was as follows (in thousands):

	Three Months Ended				Six Months Ended
	June 28, 2025		June 29, 2024		June 28, 2025		June 29, 2024
Stock awards (1)	$1,064		$3,294		$1,503		$6,438
Stock options	485		698		3,997		1,671
Total stock-based compensation expense (1)	$1,549		$3,992		$5,500		$8,109

___________________________

(1) Changes in stock-based compensation expense include the cumulative impact of the change in the expected achievements of certain performance

targets.

 10. Profit Sharing and 401(k) Plan

Under the Company’s profit sharing and 401(k) plan, eligible employees may defer up to 50% of their compensation on a

pre-tax basis, subject to Internal Revenue Service limitations. Each pay period, the Company makes a contribution equal

to a percentage of the employee’s contribution. During the three months ended June 28, 2025 and June 29, 2024, the

Company’s contributions, net of forfeitures, were $1.7 million and $1.2 million, respectively and during the six months

ended June 28, 2025 and June 29, 2024, were $3.5 million and $3.2 million, respectively.

11 | 2Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

 11. Net Loss per Common Share

The components of basic and diluted net loss per share were as follows (in thousands, except per share amounts):

	Three Months Ended				Six Months Ended
	June 28, 2025		June 29, 2024		June 28, 2025		June 29, 2024
Net loss	$(25,012)		$(5,051)		$(33,658)		$(12,533)
Reconciliation of weighted-average shares outstanding:
Basic weighted-average shares outstanding	22,903		22,614		22,804		22,560
Dilutive effect of stock-based awards	—		—		—		—
Diluted weighted-average shares outstanding	22,903		22,614		22,804		22,560
Net loss per share – basic	$(1.09)		$(0.22)		$(1.48)		$(0.56)
Net loss per share – diluted	$(1.09)		$(0.22)		$(1.48)		$(0.56)

For the three and six month periods ended June 28, 2025 and June 29, 2024, otherwise dilutive stock-based awards

have been excluded from the calculation of diluted weighted-average shares outstanding, as their inclusion would have

had an anti-dilutive effect on our net loss per diluted share. Additional potential dilutive stock-based awards totaling

1.6 million and 1.3 million for the three months ended June 28, 2025 and June 29, 2024, respectively, and 1.8 million

and 1.3 million for the six months ended June 28, 2025 and June 29, 2024, respectively, have been excluded from the

diluted net loss per share calculations because these stock-based awards were anti-dilutive.

 12. Restructuring Costs

In the fourth quarter of 2023, the Company initiated cost reduction actions to reduce operating expenses and accelerate

gross margin initiatives, and recognized $33.8 million of restructuring costs through December 28, 2024. The Company

has incurred an additional $8.4 million and of restructuring costs during the six months ended June 28, 2025. Charges

incurred related to this initiative were comprised of contract termination costs, severance and employee-related benefits,

professional fees and other, and asset impairment charges and are included in the restructuring costs line in the

Company’s condensed consolidated statement of operations. The Company expects approximately $8 million of

additional restructuring costs to be incurred through the remainder of 2025, primarily due to severance and employee-

related benefits, contract termination costs, and asset impairment charges.

The following table provides a summary of the Company’s restructuring costs during the three and six months ended

June 28, 2025 and June 29, 2024 (in thousands):

	Three Months Ended				Six Months Ended
	June 28, 2025		June 29, 2024		June 28, 2025		June 29, 2024
Cash restructuring costs:
Contract termination costs (1)	$1,409		$(230)		$1,295		$4,183
Severance and employee-related benefits	6,335		401		6,492		1,242
Professional fees and other	—		1,648		17		4,494
Total cash restructuring costs	7,744		1,819		7,804		9,919
Non-cash restructuring costs:
Asset impairments (2)	588		—		588		2,500
Total restructuring costs	$8,332		$1,819		$8,392		$12,419

____________________

(1) Primarily comprised of lease termination costs and includes changes in estimate.

(2) Primarily comprised of impairments of property and equipment.

12 | 2Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

The following table provides the activity in the Company’s restructuring related liabilities, which are included within

accounts payable, compensation and benefits and other current liabilities on the condensed consolidated balance sheet

(in thousands):

	June 28, 2025		December 28, 2024
Balance at the beginning of year	$3,341		$8,720
Expenses	7,804		14,888
Cash payments	(7,973)		(20,267)
Balance at the end of the period	$3,172		$3,341

Since the initiation of cost reduction actions in the fourth quarter of 2023, the Company has recognized a cumulative

$42.2 million of restructuring costs, as follows (in thousands):

		Cumulative
		June 28, 2025
Cash restructuring costs:
Contract termination costs (1)		$15,732
Severance and employee-related benefits		14,685
Professional fees and other		5,761
Total cash restructuring costs		36,178
Non-cash restructuring costs:
Asset impairments (2)		6,008
Total restructuring costs		$42,186

____________________

(1)Primarily comprised of lease termination costs.

(2) Includes impairments of both lease right-of-use assets and property and equipment.

13. Income Taxes

Income tax expense was $13.2 million for the three months ended June 28, 2025, compared with income tax benefit of

$1.1 million for the same period one year ago. Income tax expense totaled $12.6 million for six months ended June 28,

2025, compared with income tax benefit of $0.4 million for the same period one year ago.

The Company evaluates its deferred income taxes quarterly to determine if valuation allowances are required. As part of

this evaluation, the Company assess whether valuation allowances should be established for any deferred tax assets that

are not considered more likely than not to be realized, using all available evidence, both positive and negative. This

assessment considers, among other matters, the nature, frequency, and severity of historical losses, forecasts of future

profitability, taxable income in available carryback periods and tax planning strategies. In making such judgments,

significant weight is given to evidence that can be objectively verified. During the three months ended June 28, 2025,

the Company recorded a change in valuation allowance of $14 million on the basis of management’s reassessment of

the amount of its deferred tax assets primarily related to interest expense that are more likely than not to not be realized.

This decreased the effective tax rate by 66.5% for the three months ended June 28, 2025.  The Company continues to

assess the need for the valuation allowance and will make adjustments when appropriate.

13 | 2Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

14. Segments

The Company’s chief operating decision maker (CODM), who is the Chief Executive Officer, assesses company-wide

performance and allocates resources based on consolidated financial information. Consequently, the Company views the

entire organization as one reportable segment and the strategic purpose of all operating activities is to support that one

segment.

The CODM manages the Company’s business activities as a single operating and reportable segment at the

consolidated level. The CODM uses consolidated earnings and losses, as reported on the Company’s condensed

consolidated statement of operations, in evaluating performance of the Company in determining how to allocate

resources of the Company as a whole, including investing in the Company’s product development, sales and marketing

campaigns, and employee compensation. The measure of segment assets that is reviewed by the CODM is reported

within the condensed consolidated balance sheet as consolidated total assets. The CODM also uses consolidated

earnings or losses before interest, taxes, depreciation and amortization (Adjusted EBITDA) as the basis to evaluate the

performance of the Company.

The following is a summary of the significant expense categories and consolidated net loss details provided to the

CODM (in thousands):

	Three Months Ended				Six Months Ended
	June 28, 2025		June 29, 2024		June 28, 2025		June 29, 2024
Net Sales	$327,925		$408,413		$721,186		$878,862
Less:
Cost of sales	(134,180)		(166,923)		(286,906)		(361,198)
Marketing expenses	(62,427)		(89,483)		(160,368)		(198,512)
Selling expenses	(84,037)		(92,917)		(175,199)		(192,400)
General and administrative	(29,604)		(39,573)		(68,223)		(78,652)
Research and development	(9,420)		(11,578)		(20,323)		(24,019)
Restructuring costs	(8,332)		(1,819)		(8,392)		(12,419)
Interest expense	(11,734)		(12,270)		(22,815)		(24,569)
Income tax (expense) benefit	(13,203)		1,099		(12,618)		374
Net loss	$(25,012)		$(5,051)		$(33,658)		$(12,533)

14 | 2Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

15. Commitments and Contingencies

Warranty Liabilities

The activity in the accrued warranty liabilities account was as follows (in thousands):

	Six Months Ended
	June 28, 2025		June 29, 2024
Balance at beginning of period	$6,947		$8,503
Additions charged to costs and expenses for current-year sales	5,878		7,675
Deductions from reserves	(5,800)		(8,048)
Changes in liability for pre-existing warranties during the current year, including expirations	(983)		(171)
Balance at end of period	$6,042		$7,959

Legal Proceedings

The Company is involved from time to time in various legal proceedings arising in the ordinary course of its business,

including primarily commercial, product liability, employment and intellectual property claims. In accordance with U.S.

GAAP, the Company records a liability in its consolidated financial statements with respect to any of these matters when

it is both probable that a liability has been incurred and the amount of the liability can be reasonably estimated. If a

material loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or

range of loss is disclosed. With respect to currently pending legal proceedings, the Company has not established an

estimated range of reasonably possible material losses either because it believes that it has valid defenses to claims

asserted against it, the proceeding has not advanced to a stage of discovery that would enable it to establish an

estimate, or the potential loss is not material. The Company currently does not expect the outcome of pending legal

proceedings to have a material effect on its consolidated results of operations, financial position or cash flows. Litigation,

however, is inherently unpredictable, and it is possible that the ultimate outcome of one or more claims asserted against

the Company could adversely impact its consolidated results of operations, financial position or cash flows. The

Company expenses legal costs as incurred.

Purported Class Action Complaint

On January 14, 2025, purported customers served a putative class action complaint on behalf of themselves and a

putative class of California consumers against Sleep Number in the United States District Court for the Central District of

California alleging that Sleep Number’s beds are perpetually on sale in violation of California law. The Plaintiff seeks

injunctive relief, damages and attorney’s fees. Sleep Number brought a motion to dismiss for failure to state a claim and

a motion to transfer or, alternatively, dismiss based on the first-to-file doctrine (citing the purported class action

complaint filed on September 27, 2024 as described below). On April 8, 2025, the Court granted Sleep Number’s

motion to transfer or, alternatively, dismiss and dismissed the matter in its entirety based on the first-to-file doctrine. The

plaintiffs did not appeal the dismissal.

Purported Class Action Complaint

On September 27, 2024, a purported customer served a putative class action complaint on behalf of themself and a

putative class of California consumers against Sleep Number in the United States District Court for the Eastern District of

California alleging that Sleep Number’s beds are perpetually on sale in violation of California law. The plaintiff seeks

injunctive relief, damages and attorney’s fees.

15 | 2Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION

Table of Contents

SLEEP NUMBER CORPORATION

AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(unaudited)

16. Subsequent Event

On July 4, 2025, the One Big Beautiful Bill Act (OBBBA) was enacted into law. The OBBBA makes permanent key

elements of the Tax Cuts and Jobs Act, including 100% bonus depreciation, domestic research cost expensing, and the

business interest expense limitation. ASC 740, “Income Taxes”, requires the effects of changes in tax rates and laws on

deferred tax balances to be recognized in the period in which the legislation is enacted. Consequently, as of the date of

enactment, and during the third quarter of 2025, the Company will evaluate all deferred tax balances under the newly

enacted tax law and identify any other changes required to its financial statements as a result of the OBBBA. The

Company is currently evaluating the impact of the OBBBA on its consolidated financial statements and related

disclosures.

16 | 2Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF

OPERATIONS

Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is intended to provide

a reader of the Company’s condensed consolidated financial statements with a narrative from the perspective of

management on its financial condition, results of operations, liquidity and certain other factors that may affect the

Company’s future results. MD&A is presented in seven sections:

•Forward-Looking Statements and Risk Factors

•Business Overview

•Results of Operations

•Liquidity and Capital Resources

•Non-GAAP Data Reconciliations

•Critical Accounting Policies

Forward-looking Statements and Risk Factors

The discussion in this Quarterly Report on Form 10-Q contains certain forward-looking statements that relate to

future plans, events, financial results or performance. You can identify forward-looking statements by those that

are not historical in nature, particularly those that use terminology such as “may,” “will,” “should,” “could,”

“expect,” “anticipate,” “believe,” “estimate,” “plan,” “project,” “predict,” “intend,” “potential,” “continue” or

the negative of these or similar terms. These statements are subject to certain risks and uncertainties that could

cause actual results to differ materially from the Company’s historical experience and its present expectations or

projections. These risks and uncertainties include, among others:

•Changes in economic conditions and consumer sentiment and related impacts on discretionary consumer spending;

•Interest rates remain elevated, and may further increase and impact the cost of servicing the Company’s

indebtedness;

•Access to alternative financing options may depend on factors beyond the Company’s control or require the

Company to accept unfavorable terms;

•Availability of attractive and cost-effective consumer credit options;

•Ability to achieve cost savings, efficiencies and other benefits from its business restructuring actions and to avoid

adverse effects;

•Effectiveness and efficiency of the Company’s marketing strategy and promotions;

•Ability to execute Sleep Number’s Total Retail distribution strategy;

•Ability to compete effectively;

•Ability to achieve and maintain high levels of product and service quality;

•Ability to improve and expand the product line and execute new product introductions;

•Ability to protect the Company’s technology, trademarks and brand, and the adequacy of its intellectual property

rights;

•Dependence on, and ability to maintain working relationships with key suppliers and third parties, including some

that are the only source of supply or services currently used by the Company;

•Fluctuations in commodity costs or third-party delivery or logistics costs and other inflationary pressures;

•Risks inherent in global-sourcing activities, including tariffs, foreign regulation, geo-political turmoil, war, pandemics,

labor challenges, foreign currency fluctuations, inflation, climate or other disasters and resulting supply shortages,

and production and delivery delays and disruptions;

•Operating with minimal levels of inventory, which may leave the Company vulnerable to supply shortages;

•Risks of disruption in the operation of any of the Company’s facilities and operations, including manufacturing,

assembly, distribution, logistics, field services, home delivery, headquarters, product development, retail or customer

service operations;

•Ability to effectively complete potential future acquisitions and business combinations;

•Sleep Number’s ability, and the ability of its suppliers and vendors, to attract, retain and motivate qualified and

effective personnel;

17 | 2Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION

Table of Contents

•Ability to comply with existing and changing government regulations and laws, and to commercialize new products

and innovations that meet those existing and changing government regulations and laws;

•Ability to identify and withstand cyber threats that could compromise the security of the Company’s systems or those

of third parties upon which it relies and could result in a data breach or business disruption;

•Risks associated with advancements in or adoption of artificial intelligence technologies;

•Adequacy of the Company’s and third-party information systems, and costs and disruptions related to upgrading or

maintaining these systems;

•Volatility of Sleep Number stock, its removal from various stock indices and the potential negative effects of

shareholder activism or of changes in coverage by securities analysts;

•Unfavorable tax treatment;

•Environmental, social and governance risks, including increasing scrutiny and evolving regulatory and stakeholder

expectations; and

•Ability to adapt to climate change and readiness for legal or regulatory responses thereto.

Additional information concerning these, and other risks and uncertainties is contained under the caption “Risk

Factors” in Part I, Item 1A. in the Company’s Annual Report on Form 10-K and in Part II. Item 1A. in subsequent

Quarterly Reports on Form 10-Q.

The Company has no obligation to publicly update or revise any of the forward-looking statements contained in this

Quarterly Report on Form 10-Q.

Business Overview

Sleep Number is a wellness company and market leader in the design, manufacturing, marketing and distribution of

highly innovative sleep solutions. The Company’s purpose is to improve the health and wellbeing of society through

higher quality sleep; to date, it has improved the lives of nearly 16 million people. Sleep Number’s Smart Sleepers

benefit from individualized sleep experiences, night after night, and are experiencing the physical, mental and emotional

benefits of life-changing sleep.

Sleep Number’s life-changing, differentiated smart beds combine physical and digital innovations, integrating

unparalleled physical comfort with a highly advanced sleep wellness platform. The smart beds offer the Company’s

signature firmness adjustability, enabling each sleeper adjustable comfort. Embedded digital sensors learn the sleep

needs of each individual; “sense and do” technology uses the sensed data to automatically adjust the smart bed to keep

the sleeper comfortable throughout the night. Active temperature balancing technology supports the ideal climate for

each sleeper and solves a prevalent sleep challenge. Additionally, the smart beds are an exceptional value, with

personalized sleep insights delivered daily, new features regularly added to all smart beds through over-the-air updates

and prices to meet most budgets. Sleep Number® smart beds provide unmatched features, benefits and comfort that

can lead to improved sleep health and wellness for both sleepers.

The Company’s advantaged business model is supported by its consumer innovation strategy: an individualized, digital

sleep wellness platform, a network of millions of highly engaged Smart Sleepers who are loyal brand advocates, a

vertically integrated operating model and a culture of individuality, with an ambitious vision to become one of the

world’s most beloved brands.

The Company’s 3,400 mission-driven team members are dedicated to the Company’s mission of improving lives by

individualizing sleep experiences. They passionately innovate to drive value creation, including our exclusive direct-to-

consumer selling in 630 stores and online, which meets customers whenever and wherever they choose to provide an

exceptional experience and a lifelong relationship. Additionally, the Company partners with world-leading institutions to

bring the power of 34 billion hours of longitudinal sleep data to sleep science and research.

The bedding industry has been in a sector level recession for three years with mattress industry unit volumes returning to

an estimated 24 million units in 2024, the lowest level since 2015. Consumer sentiment remains well below historical

averages, and high interest rates are putting ongoing pressure on the housing market. Consumers continue to scrutinize

spending, with inflation and other factors weighing on their purchasing power. Since initiating the Company’s operating

model transformation in the fourth quarter of 2023, the Company has executed structural changes to reduce fixed

expenses, while prioritizing improving margins and generating cash to create greater financial resilience across market

cycles.

18 | 2Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION

Table of Contents

On July 4, 2025, the One Big Beautiful Bill Act (OBBBA) was enacted into law. The OBBBA makes permanent key

elements of the Tax Cuts and Jobs Act, including 100% bonus depreciation, domestic research cost expensing, and the

business interest expense limitation. The Company is currently evaluating the impact of the OBBBA on its consolidated

financial statements and related disclosures.

Results of Operations

Quarterly and Year-to-Date Results

Quarterly and year-to-date operating results may fluctuate significantly as a result of a variety of factors, including

increases or decreases in sales, timing, amount and effectiveness of advertising expenditures, changes in sales return

rates or warranty experience, timing of investments in growth initiatives and infrastructure, timing of store openings/

closings and related expenses, changes in net sales resulting from changes in the Company’s store base, timing of new

product introductions and related expenses, timing of promotional offerings, competitive factors, changes in commodity

costs, disruptions in global supplies or third-party service providers, seasonality of retail and bedding industry sales,

consumer sentiment and general economic conditions. The extent to which these external factors will impact the

Company’s business and its consolidated financial results will depend on future developments, which are highly

uncertain and cannot be predicted. Therefore, the historical results of operations may not be indicative of the results that

may be achieved for any future period.

Highlights

Financial highlights for the three months ended June 28, 2025 were as follows:

•Net sales for the three months ended June 28, 2025 of $328 million decreased 20% from $408 million for the same

period one year ago driven by lower volume and reduced store count.

•The net sales change resulted from a 19% Total Retail comparable sales decrease. For additional details, see the

components of total net sales change on page 20.

•Average sales per store (sales for stores open at least one year, Total Retail, including online, phone and chat) on a

trailing twelve-month basis for the period ended June 28, 2025 totaled $2.4 million, compared with $2.7 million for

the same period one year ago.

•Operating loss for the three months ended June 28, 2025 was $0.1 million, compared with operating income of

$6.1 million for the same period one year ago. The $6 million decrease in operating income was driven by the lower

net sales and an increase in restructuring expenses of $7 million; partially offset by a $42 million reduction in

operating expenses.

•Adjusted EBITDA for the three months ended June 28, 2025 was $24 million, compared to $28 million for the same

period one year ago. The decrease was primarily due a higher level of net loss.

•Gross profit rate of 59.1% for both the three months ended June 28, 2025 and June 29, 2024. See the gross profit

discussion on page 21 for additional details.

•The $42 million year-over-year reduction in the Company’s operating expenses was due to lower sales and

marketing expenses, general and administrative expenses, and research and development expenses, partially offset

by higher restructuring costs.

•Net loss for the three months ended June 28, 2025 was $25 million, compared with $5 million for the same period

one year ago. Net loss per diluted share was $1.09, compared with $0.22 for the same period one year ago.

•The Company’s adjusted return on invested capital (Adjusted ROIC) was 8.4% on a trailing twelve-month basis for

the period ended June 28, 2025, compared with 3.7% for the comparable period one year ago.

•The Company provided $1 million in cash from operating activities for the six months ended June 28, 2025,

compared with $24 million for the same period one year ago.

•Free cash flow used $7 million for the six months ended June 28, 2025, compared with providing $9 million for the

same period one year ago.

•As of June 28, 2025, the Company had $564 million of borrowings under its revolving credit facility.

19 | 2Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION

Table of Contents

The following table sets forth the Company’s results of operations expressed as dollars and percentages of net sales.

Figures are in millions, except percentages and per share amounts. Amounts may not add due to rounding differences.

	Three Months Ended								Six Months Ended
	June 28, 2025				June 29, 2024				June 28, 2025				June 29, 2024
Net sales	$327.9		100.0%		$408.4		100.0%		$721.2		100.0%		$878.9		100.0%
Cost of sales	134.2		40.9%		166.9		40.9%		286.9		39.8%		361.2		41.1%
Gross profit	193.7		59.1%		241.5		59.1%		434.3		60.2%		517.7		58.9%
Operating expenses:
Sales and marketing	146.5		44.7%		182.4		44.7%		335.6		46.5%		390.9		44.5%
General and administrative	29.6		9.0%		39.6		9.7%		68.2		9.5%		78.7		8.9%
Research and development	9.4		2.9%		11.6		2.8%		20.3		2.8%		24.0		2.7%
Restructuring costs	8.3		2.5%		1.8		0.4%		8.4		1.2%		12.4		1.4%
Total operating expenses	193.8		59.1%		235.4		57.6%		432.5		60.0%		506.0		57.6%
Operating (loss) income	(0.1)		—%		6.1		1.5%		1.8		0.2%		11.7		1.3%
Interest expense, net	11.7		3.6%		12.3		3.0%		22.8		3.2%		24.6		2.8%
Loss before income taxes	(11.8)		(3.6%)		(6.2)		(1.5%)		(21.0)		(2.9%)		(12.9)		(1.5%)
Income tax expense (benefit)	13.2		4.0%		(1.1)		(0.3%)		12.6		1.7%		(0.4)		0.0%
Net loss	$(25.0)		(7.6%)		$(5.1)		(1.2%)		$(33.7)		(4.7%)		$(12.5)		(1.4%)
Net loss per share:
Basic	$(1.09)				$(0.22)				$(1.48)				$(0.56)
Diluted	$(1.09)				$(0.22)				$(1.48)				$(0.56)
Weighted-average number of common shares:
Basic	22.9				22.6				22.8				22.6
Diluted	22.9				22.6				22.8				22.6

The percentage of total net sales, by dollar volume, was as follows:

	Three Months Ended				Six Months Ended
	June 28, 2025		June 29, 2024		June 28, 2025		June 29, 2024
Retail stores	87.8%		87.8%		87.7%		88.0%
Online, phone, chat and other	12.2%		12.2%		12.3%		12.0%
Total Company	100.0%		100.0%		100.0%		100.0%

20 | 2Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION

Table of Contents

The components of total net sales change, including comparable net sales changes, were as follows:

	Three Months Ended				Six Months Ended
	June 28, 2025		June 29, 2024		June 28, 2025		June 29, 2024
Sales change rates:
Retail comparable-store sales (1)	(18%)		(11%)		(17%)		(10%)
Online, phone and chat	(19%)		(13%)		(16%)		(16%)
Total Retail comparable sales change (1)	(19%)		(11%)		(17%)		(11%)
Net opened/closed stores and other	(1%)		0%		(1%)		0%
Total Company	(20%)		(11%)		(18%)		(11%)

___________________________

(1)Stores are included in the comparable-store calculations in the 13th full month of operations. Stores that have been remodeled or repositioned

within the same shopping center remain in the comparable-store base.

Other sales metrics were as follows:

	Three Months Ended				Six Months Ended
	June 28, 2025		June 29, 2024		June 28, 2025		June 29, 2024
Average sales per store (1) (in thousands)	$2,395		$2,732
Average sales per square foot (1)	$775		$883
Stores > $2 million in net sales (2)	47%		62%
Stores > $3 million in net sales (2)	13%		21%
Average revenue per smart bed unit – Total Retail (3)	$5,880		$5,802		$5,940		$5,782

___________________________

(1)Trailing-twelve months Total Retail comparable sales per store open at least one year.

(2)Trailing-twelve months for stores open at least one year (excludes online, phone and chat sales).

(3)Represents Total Retail net sales divided by Total Retail smart bed units.

The number of retail stores operating was as follows:

	Three Months Ended				Six Months Ended
	June 28, 2025		June 29, 2024		June 28, 2025		June 29, 2024
Beginning of period	637		661		640		672
Opened	1		4		3		10
Closed	(8)		(19)		(13)		(36)
End of period	630		646		630		646

21 | 2Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION

Table of Contents

Comparison of Three Months Ended June 28, 2025 with Three Months Ended June 29, 2024

Net sales

Net sales for the three months ended June 28, 2025 of $328 million decreased 20% from $408 million for the same

period one year ago driven by lower volume and reduced store count. The net sales change consisted primarily of a 19%

Total Retail comparable sales decrease.

The $80 million net sales decrease compared with the same period one year ago was comprised of the following: (i) a

$64 million decrease in Retail comparable net sales; (ii) a $9 million decrease from online, phone and chat; and (iii) a $7

million decrease from net store closings and other. Total Retail smart bed unit sales decreased 20% compared with the

prior year. Total Retail average revenue per smart bed unit increased by 1% to $5,880, compared with $5,802 in the

prior-year period.

Gross profit

Gross profit of $194 million for the three months ended June 28, 2025 decreased by $48 million, or 20%, compared with

$241 million for the same period one year ago. The gross profit rate totaled 59.1% of net sales for both the three months

ended June 28, 2025 and June 29, 2024.

The current-year gross profit rate was consistent with the prior-year period and was affected by the following items: (i)

year-over-year product cost reductions through value engineering and ongoing supplier negotiations, increased the rate

by 1.4 ppt; offset by (ii) an unfavorable product mix which deleveraged the rate by 1.1 ppt; and (iii) warranty expenses

along with return and exchange costs which deleveraged the rate by 0.3 ppt.

Sales and marketing expenses

Sales and marketing expenses for the three months ended June 28, 2025 were $146 million, or 44.7% of net sales,

compared with $182 million, or 44.7% of net sales, for the same period one year ago. The current-year sales and

marketing expenses rate was consistent with the same period one year ago primarily due to the deleveraging impact of

an 20% net sales decline, partially offset by a 20% decrease in sales and marketing expenses including a 32% lower

media spend.

General and administrative expenses

General and administrative (G&A) expenses totaled $30 million, or 9.0% of net sales, for the three months ended

June 28, 2025, compared with $40 million, or 9.7% of net sales, in the prior-year period. The changes in G&A expenses

consisted mainly of: (i) a $6.1 million year-over-year decrease in company-wide, performance-based incentive

compensation and (ii) a $1.7 million decrease in employee compensation; (iii) a $1.1 million decrease in depreciation and

amortization; and (iv) a $1.0 million decrease in professional and consulting fees. The G&A expenses rate decreased by

0.7 ppt. in the current-year period, compared with the same period one year ago due to the items discussed above

offset by the deleveraging impact of lower net sales.

Research and development expenses

Research and development (R&D) expenses totaled $9 million for the three months ended June 28, 2025, compared

with $12 million with the same period one year ago. The changes in R&D expenses were primarily due to lower

headcount and outside services. Moving forward, the Company’s innovation agenda will focus on maintaining and

improving the Company’s core technologies and introducing additional advancements, while driving costs out of the

product.

Interest expense, net

Interest expense, net totaled $12 million for both the three months ended June 28, 2025, and June 29, 2024.

The increase in the average debt outstanding compared to the same period one year ago was offset by a lower

weighted-average interest rate.

22 | 2Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION

Table of Contents

Restructuring Costs

Restructuring costs for the three months ended June 28, 2025 were $8 million , compared with $2 million for the same

period one year ago. Charges incurred related to this initiative were comprised of contract termination costs, severance

and employee-related benefits, professional fees and other, and asset impairment charges and are included in the

restructuring costs line in the Company’s condensed consolidated statement of operations. The Company expects an

additional $8 million of restructuring costs to be incurred through the remainder of 2025, primarily due to severance and

employee-related benefits, contract termination costs, and asset impairment charges. See Note 12, Restructuring Costs,

of the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1, Financial Information, of this

Quarterly Report on Form 10-Q for further information on restructuring costs.

Income tax expense (benefit)

Income tax expense was $13.2 million for the three months ended June 28, 2025, compared with income tax benefit of

$1.1 million for the same period one year ago.

The Company evaluates its deferred income taxes quarterly to determine if valuation allowances are required. As part of

this evaluation, the Company assess whether valuation allowances should be established for any deferred tax assets that

are not considered more likely than not to be realized, using all available evidence, both positive and negative. This

assessment considers, among other matters, the nature, frequency, and severity of historical losses, forecasts of future

profitability, taxable income in available carryback periods and tax planning strategies. In making such judgments,

significant weight is given to evidence that can be objectively verified. During the three months ended June 28, 2025,

the Company recorded a change in valuation allowance of $14 million on the basis of management’s reassessment of

the amount of its deferred tax assets primarily related to interest expense that are more likely than not to not be realized.

This decreased the effective tax rate by 66.5% for the three months ended June 28, 2025.  The Company continues to

assess the need for the valuation allowance and will make adjustments when appropriate.

Comparison of Six Months Ended June 28, 2025 with Six Months Ended June 29, 2024

Net sales

Net sales for the six months ended June 28, 2025 decreased by $158 million, or 18%, to $721 million, compared with

$879 million for the same period one year ago driven by lower volume and reduced store count.

The net sales decrease consisted primarily of a 17% comparable sales decrease in Total Retail. For additional details, see

the components of total net sales change on page 20.

The $158 million net sales decrease compared with the same period one year ago was comprised of the following: (i) a

$124 million decrease in Retail comparable net sales; (ii) a $17 million decrease in online, phone and other sales; and (iii)

a $17 million decrease resulting from net store closings. Total smart bed unit sales declined 20% compared with the

same period one year ago. Average revenue per smart bed unit in Total Retail increased by 3% to $5,940, compared

with $5,782 in the prior-year period.

Gross profit

Gross profit of $434 million for the six months ended June 28, 2025 decreased by $83 million, or 16%, compared with

$518 million for the same period one year ago. The gross profit rate increased to 60.2% of net sales for the six months

ended June 28, 2025, compared to 58.9% in the prior-year comparable period.

The current-year gross profit rate increase of 1.3 ppt. was impacted by: (i) year-over-year product cost reductions

through value engineering and ongoing supplier negotiations, increased the rate by 2.3 ppt; offset by (ii) an unfavorable

product mix which deleveraged the rate by 1.0 ppt

Sales and marketing expenses

Sales and marketing expenses for the six months ended June 28, 2025 were $336 million, or 46.5% of net sales,

compared with $391 million, or 44.5% of net sales, for the same period one year ago. The current-year sales and

marketing expenses rate increase of 2.0 ppt. was primarily due to deleveraging impact of an 18% net sales decline offset

by a 14% decrease in expenses including 19% lower media spend.

23 | 2Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION

Table of Contents

General and administrative expenses

General and administrative (G&A) expenses totaled $68 million, or 9.5% of net sales, for the six months ended June 28,

2025, compared with $79 million, or 8.9% of net sales, in the prior-year period. The $11 million decrease in G&A

expenses consisted of: (i) a $7.5 million year-over-year decrease in company-wide, performance-based incentive

compensation and (ii) a $2.0 million decrease in depreciation and amortization; and (iii) a $1.5 million decrease in

employee compensation; offset by a (iv) a $0.6 million increase in professional and consulting fees primarily related to

proxy contest and CEO search costs that occurred during the first quarter of 2025. The G&A expenses rate increased by

0.6 ppt. in the current-year period, compared with the same period one year ago due to the deleveraging impact of

the 18% net sales decrease.

Research and development expenses

Research and development (R&D) expenses decreased by 15% to $20 million for the six months ended June 28, 2025,

compared with $24 million for the same period one year ago on lower outside services and headcount. While the

Company’s consumer innovation pipeline remains robust, it is re-prioritizing R&D resources in this highly constrained

environment. Moving forward, the Company’s innovation agenda will focus on maintaining and improving the

Company’s core technologies and introducing additional advancements, while driving costs out of the product.

Interest expense, net

Interest expense, net decreased to $23 million for the six months ended June 28, 2025, compared with $25 million for

the same period one year ago. The $2 million decrease was primarily driven by a lower weighted-average interest rate

compared with the same period one year ago.

Restructuring costs

Restructuring costs for the six months ended June 28, 2025 were $8 million, compared with $12 million for the same

period one year ago. Charges incurred related to this initiative were comprised of contract termination costs, severance

and employee-related benefits, professional fees and other, and asset impairment charges and are included in the

restructuring costs line in the Company’s condensed consolidated statement of operations. The Company expects an

additional $8 million of restructuring costs to be incurred through the remainder of 2025, primarily due to severance and

employee-related benefits, contract termination costs, and asset impairment charges. See Note 12, Restructuring Costs,

of the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1, Financial Information, of this

Quarterly Report on Form 10-Q for further information on restructuring costs.

Income tax expense (benefit)

Income tax expense totaled $12.6 million for the six months ended June 28, 2025, compared with income tax benefit of

$0.4 million for the same period one year ago.

The Company evaluates its deferred income taxes on a quarterly basis to determine if valuation allowances are required.

As part of this evaluation, the Company assess whether valuation allowances should be established for any deferred tax

assets that are not considered more likely than not to be realized, using all available evidence, both positive and

negative. This assessment considers, among other matters, the nature, frequency, and severity of historical losses,

forecasts of future profitability, taxable income in available carryback periods and tax planning strategies. In making such

judgments, significant weight is given to evidence that can be objectively verified. A valuation allowance of $14 million

that was recorded during the six months ended June 28, 2025. The valuation allowance primarily related to deferred tax

assets on interest expense that are more likely than not to not be realized. The Company continues to assess the need

for the valuation allowance and will make adjustments when appropriate.

24 | 2Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION

Table of Contents

Liquidity and Capital Resources

Managing liquidity and capital resources is an important part of the Company’s commitment to deliver superior

shareholder value over time.

The Company’s primary sources of liquidity are cash flows provided by operating activities and cash available under its

$673 million revolving credit facility, as amended. As of June 28, 2025, the Company does not have any off-balance

sheet financing other than its $7 million in outstanding letters of credit. The cash generated from ongoing operations

and cash available under the revolving credit facility are expected to be adequate to maintain operations, and fund

anticipated expansion, strategic initiatives and contractual obligations such as lease payments and capital commitments

for new retail stores for the foreseeable future.

Cash and cash equivalents totaled $1.3 million and $2.0 million at June 28, 2025 and December 28, 2024, respectively.

Significant changes in cash and cash equivalents during the six months ended June 28, 2025 primarily consisted of

$1 million of cash provided by operating activities, $11 million of cash used in investing activities, a $12 million increase

in short-term borrowings, offset by $2 million used for debt issuance costs.

The following table summarizes cash flows (in millions). Amounts may not add due to rounding differences:

	Six Months Ended
	June 28, 2025		June 29, 2024
Total cash provided by (used in) :
Operating activities	$1.2		$23.5
Investing activities	(11.3)		(17.0)
Financing activities	9.5		(7.0)
Net decrease in cash and cash equivalents	$(0.6)		$(0.5)

Net cash provided by operating activities for the six months ended June 28, 2025 was $1 million, compared with net

cash provided by operating activities of $24 million for the six months ended June 29, 2024. Significant components of

the year-over-year change in cash provided by operating activities included: (i) a $21 million year-over-year increase in

net loss; (ii) a $17 million fluctuation in the amount of compensation and benefits accrued and timing of the related

payments resulting from year-over-year changes in Company-wide performance-based incentive compensation; (iii) a

$16 million fluctuation in inventory as last year benefited from reduction in inventory levels driven by operational

improvements; (iv) a $5 million decrease in depreciation and amortization due to recent lower capital spending levels

and restructuring related fixed asset impairments, and (iv) a $5 million fluctuation in accounts receivable due to lower

sales volumes and timing of orders; offset by (v) a $27 million fluctuation in accounts payable due to lower expenses in

the current year and timing of payments; (vi) a $12 million fluctuation in prepaid expenses.

Net cash used in investing activities for the six months ended June 28, 2025 was $11 million, compared with $17 million

for the six months ended June 29, 2024. Cash used to purchase property and equipment was $8 million for the six

months ended June 28, 2025, compared with $14 million for the same period one year ago. In addition, the Company

used $3 million cash for payment to secure contractual rights during the six months ended June 29, 2024.

Net cash provided by financing activities was $10 million for the six months ended June 28, 2025, compared with net

cash used in financing activities of $7 million for the same period one year ago. Short-term borrowings increased by

$12 million during the current-year period due to an $17 million increase in borrowings under the revolving credit facility

to $564 million and a $5 million decrease in book overdrafts, which are included in the net change in short-term

borrowings. During the six months ended June 28, 2025, the Company used $2 million of cash for debt issuance costs

related to the credit facility amendment during the first quarter of 2025. During both the six months ended June 28,

2025 and June 29, 2024, the Company repurchased $1 million of its stock in connection with the vesting of employee

restricted stock awards.

In the second quarter of fiscal 2022, the Company suspended share repurchases under its Board-approved share

repurchase program. At June 28, 2025, there was $348 million remaining authorization under the Board-approved

$600 million share repurchase program. There is no expiration date governing the period over which the Company can

repurchase shares. The Company made no share repurchases under its Board-approved share repurchase program in

either period.

25 | 2Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION

Table of Contents

At June 28, 2025, the Company had $564 million of borrowings under its revolving credit facility, $7 million in

outstanding letters of credit and net liquidity available under the credit facility of $102 million. Total availability under its

revolving credit facility was $673 million, which amortizes by $2.5 million per quarter through December 2026. At

June 28, 2025, the Company’s leverage ratio as defined in the credit agreement was 4.6x versus the permissible net

leverage ratio of 4.75x, the weighted-average interest rate on borrowings under the credit facility was 7.9% and the

Company was in compliance with all financial covenants.

Non-GAAP Data Reconciliations

Earnings before Interest, Taxes, Depreciation and Amortization (Adjusted EBITDA)

The Company defines earnings before interest, taxes, depreciation and amortization (Adjusted EBITDA) as net loss plus:

income tax expense (benefit), interest expense, depreciation and amortization, stock-based compensation, restructuring

costs, CEO transition/proxy contest costs and asset impairments. Management believes Adjusted EBITDA is a useful

indicator of the Company’s financial performance and its ability to generate cash from operating activities. The

Company’s definition of Adjusted EBITDA may not be comparable to similarly titled definitions used by other

companies. The table below reconciles Adjusted EBITDA, which is a non-GAAP financial measure, to the comparable

GAAP financial measure.

Adjusted EBITDA calculations are as follows (in thousands):

	Three Months Ended				Trailing-Twelve Months Ended
	June 28, 2025		June 29, 2024		June 28, 2025		June 29, 2024
Net loss	$(25,012)		$(5,051)		$(41,459)		$(40,039)
Income tax expense (benefit)	13,203		(1,099)		7,830		(10,730)
Interest expense	11,734		12,270		46,614		48,214
Depreciation and amortization	13,697		16,347		59,590		69,676
Stock-based compensation	1,549		3,992		8,835		13,073
Restructuring costs (1)	8,332		1,819		14,039		28,147
CEO transition/Proxy contest costs (2)	53		—		2,825		—
Asset impairments	—		—		1,220		490
Adjusted EBITDA	$23,556		$28,278		$99,494		$108,831

_____________________

(1) Represents costs related to business restructuring actions initiated in the fourth quarter of fiscal 2023.

(2) Represents costs related to CEO transition activities and proxy contest costs of $0.1 million and $0, respectively, for the three months ended

June 28, 2025 and $0.8 million and $2.0 million, respectively, for the trailing twelve months ended June 28, 2025. These costs were both initiated in

the fourth quarter of fiscal 2024.

Free Cash Flow

The Company’s “free cash flow” data is considered a non-GAAP financial measure and is not in accordance with, or

preferable to, “net cash provided by operating activities,” or GAAP financial data. However, the Company is providing

this information as it believes it facilitates analysis for investors and financial analysts.

The following table summarizes free cash flow calculations (in thousands):

	Six Months Ended				Trailing-Twelve Months Ended
	June 28, 2025		June 29, 2024		June 28, 2025		June 29, 2024
Net cash provided by (used in) operating activities	$1,196		$23,518		$(9,228)		$(4,230)
Subtract: Purchases of property and equipment	8,052		14,075		18,796		41,232
Free cash flow	$(6,856)		$9,443		$(28,024)		$(45,462)

26 | 2Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION

Table of Contents

Non-GAAP Data Reconciliations (continued)

Return on Invested Capital (Adjusted ROIC)

Adjusted ROIC is a financial measure the Company uses to determine how efficiently it deploys its capital. It quantifies

the return the Company earns on its adjusted invested capital. Management believes Adjusted ROIC is also a useful

metric for investors and financial analysts. The Company computes Adjusted ROIC as outlined below. Its definition and

calculation of Adjusted ROIC may not be comparable to similarly titled definitions and calculations used by other

companies.

The tables below reconcile adjusted net operating profit after taxes (Adjusted NOPAT) and total adjusted invested

capital, which are non-GAAP financial measures, to the comparable GAAP financial measures (in thousands):

	Trailing-Twelve Months Ended
	June 28, 2025		June 29, 2024
Adjusted net operating profit after taxes (Adjusted NOPAT)
Operating income	$12,983		$(2,555)
Add: Operating lease expense (1)	25,535		27,750
Less: Income taxes (2)	1,500		(6,104)
Adjusted NOPAT	$40,018		$19,091
Average adjusted invested capital
Total deficit	$(480,688)		$(446,964)
Add: Long-term debt (3)	564,101		540,480
Add: Operating lease obligations (4)	369,794		408,724
Total adjusted invested capital at end of period	$453,207		$502,240
Average adjusted invested capital (5)	$477,676		$509,369
Adjusted return on invested capital (Adjusted ROIC) (6)	8.4%		3.7%

___________________________

(1) Represents the interest expense component of lease expense included in the Company’s financial statements under ASC 842, Leases.

(2) Reflects annual effective income tax rates, before discrete adjustments, of (3.9)% and 24.2% for June 28, 2025 and June 29, 2024, respectively.

(3) Long-term debt includes existing finance lease liabilities.

(4) Reflects operating lease liabilities included in the Company’s financial statements under ASC 842.

(5) Average adjusted invested capital represents the average of the last five fiscal quarters’ ending adjusted invested capital balances.

(6) Adjusted ROIC equals Adjusted NOPAT divided by average adjusted invested capital.

Note - the Company’s adjusted ROIC calculation and data are considered non-GAAP financial measures and are not in accordance with, or preferable

to, GAAP financial data. However, the Company is providing this information as it believes it facilitates analysis of the Company's financial performance

by investors and financial analysts.

GAAP - generally accepted accounting principles in the U.S.

Critical Accounting Policies

The Company discusses its critical accounting policies and estimates in Management’s Discussion and Analysis of

Financial Condition and Results of Operations in the Company’s Annual Report on Form 10-K for the fiscal year ended

December 28, 2024. There were no significant changes in the Company’s critical accounting policies since the end of

fiscal 2024.

27 | 2Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION

Table of Contents

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The Company is exposed to changes in market-based short-term interest rates that will impact net interest expense. If

overall interest rates were one percentage point higher than current rates, annual net income would decrease by

$5.9 million based on the $564 million of borrowings under the credit facility at June 28, 2025. The Company does not

manage the interest-rate volatility risk of borrowings under the credit facility through the use of derivative instruments.

ITEM 4. CONTROLS AND PROCEDURES

Conclusions Regarding the Effectiveness of Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures, as defined in Exchange Act Rule 13a-15(e), that are

designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under

the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time

periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is

accumulated and communicated to the Company’s management, including its principal executive officer and principal

financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required

disclosure. The Company’s management, with the participation of its principal executive officer and principal financial

officer, evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures as

of the end of the period covered by this quarterly report. Based on this evaluation, its principal executive officer and

principal financial officer concluded that the Company’s disclosure controls and procedures were effective as of the end

of the period covered by this quarterly report.

Changes in Internal Control

There were no changes in the Company’s internal control over financial reporting during the fiscal quarter ended

June 28, 2025, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control

over financial reporting.

28 | 2Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION

Table of Contents

PART II: OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The Company’s legal proceedings are discussed in Note 15 – Commitments and Contingencies, Legal Proceedings, of

the Notes to Condensed Consolidated Financial Statements included in Part I, Item 1, Notes to Condensed

Consolidated Financial Statements, of this Quarterly Report on Form 10-Q.

ITEM 1A. RISK FACTORS

The Company’s business, financial condition and operating results are subject to a number of risks and uncertainties,

including both those that are specific to the Company’s business and others that affect all businesses operating in a

global environment. Investors should carefully consider the information in this report under the heading, Management’s

Discussion and Analysis of Financial Condition and Results of Operations, and also the information under the heading,

Risk Factors, in the Company’s most recent Annual Report on Form 10-K and in subsequent Quarterly Reports on

Form 10-Q. The risk factors discussed in the Annual Report on Form 10-K and in subsequent Quarterly Reports on Form

10-Q including this Quarterly Report on Form 10-Q do not identify all risks that the Company faces because its business

operations could also be affected by additional risk factors that are not presently known to the Company or that it

currently considers to be immaterial to its operations.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS, AND ISSUER PURCHASES OF

EQUITY SECURITIES

(a) – (b) Not applicable.

(c) Issuer Purchases of Equity Securities

Period		Total Number of Shares Purchased(1)(2)		Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs(1)		Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs(3)
March 29, 2025 through April 26, 2025		4,459		$5.03		—		$348,071,000
April 27, 2025 through May 24, 2025		426		$8.87		—		$348,071,000
May 25, 2025 through June 28, 2025		33,573		$10.57		—		$348,071,000
Total		38,458		$9.91		—		$348,071,000

___________________________

(1)The Company did not purchase any shares under its Board-approved $600 million share repurchase program (effective April 4, 2021), during the

three months ended June 28, 2025.

(2)In connection with the vesting of employee restricted stock grants, the Company repurchased 38,458 shares of its common stock at a cost of

$0.4 million during the three months ended June 28, 2025.

(3)There is no expiration date governing the period over which the Company can repurchase shares under its Board-approved share repurchase

program. Any repurchased shares are constructively retired and returned to an unissued status.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

29 | 2Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION

Table of Contents

ITEM 5. OTHER INFORMATION

Rule 10b5-1 Trading Plan and Non-rule 10b5-1 Trading Arrangement Adoptions, Modifications and Terminations

During the quarter ended June 28, 2025, none of the Company’s directors or officers adopted, modified or terminated

any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the

affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” as defined in Item 408 of

SEC Regulation S-K.

30 | 2Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION

Table of Contents

ITEM 6. EXHIBITS

Exhibit Number		Description
10.1*		Fourth Amendment, dated May 27, 2025, to Lease Agreement between Legacy 1001 Minneapolis Venture, LLC, as Landlord, and Sleep Number Corporation, as Tenant, dated October 21, 2016, as amended
10.2†		Amendment No. 2 to the Sleep Number Corporation 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 contained in Sleep Number’s Current Report on Form 8-K filed May 29, 2025 (File No. 000-25121))
10.3†		Interim Chief Financial Officer Agreement (incorporated by reference to Exhibit 10.1 contained in Sleep Number’s Current Report on Form 8-K filed July 22, 2025 (File No. 000-25121))
31.1*		Certification of CEO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*		Certification of CFO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*		Certification of CEO pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350
32.2*		Certification of CFO pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350
101.INS*		Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH*		Inline XBRL Taxonomy Extension Schema Document
101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*		Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

*Filed Herein.

†        Management contract or compensatory plan or arrangement.

31 | 2Q 2025 FORM 10-Q SLEEP NUMBER CORPORATION

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be

signed on its behalf by the undersigned thereunto duly authorized.

		SLEEP NUMBER CORPORATION
		(Registrant)
Dated:	July 31, 2025	By:	/s/ Linda Findley
			Linda Findley
			Chief Executive Officer
			(principal executive officer)
		By:	/s/ Kelly F. Baker
			Kelly F. Baker
			Interim Principal Accounting Officer
			(principal accounting officer)

FAQ

How much did Sleep Number (SNBR) revenue fall in Q2 2025?

Net sales dropped 20% YoY to $327.9 million.

What is Sleep Number's current debt level?

Borrowings under the revolving credit facility total $563.9 million with a 7.9% weighted-average interest rate.

Is Sleep Number in compliance with its credit covenants?

Yes. Leverage is 4.6×, below the amended 4.75× limit, and liquidity availability is $102 million vs. a $40 million minimum.

What are the latest earnings figures for SNBR?

Q2 2025 showed a $25.0 million net loss (–$1.09 per diluted share); six-month loss is $33.7 million.

How much free cash flow did SNBR generate in 2025 so far?

Free cash flow was –$6.9 million for the first six months of 2025.

What restructuring charges has Sleep Number recorded?

Cumulative restructuring costs since Q4 2023 are $42.2 million; an additional ~$8 million is expected in 2H 2025.

What impact could the One Big Beautiful Bill Act have?

Management is evaluating OBBBA; possible benefits include 100% bonus depreciation and R&D expensing, but no quantitative effect yet provided.